UA89940C2 - 3-phenylpropionic acid derivatives - Google Patents

3-phenylpropionic acid derivatives

Info

Publication number
UA89940C2
UA89940C2 UAA200709387A UAA200709387A UA89940C2 UA 89940 C2 UA89940 C2 UA 89940C2 UA A200709387 A UAA200709387 A UA A200709387A UA A200709387 A UAA200709387 A UA A200709387A UA 89940 C2 UA89940 C2 UA 89940C2
Authority
UA
Ukraine
Prior art keywords
alkyl
aryl
acid derivatives
phenylpropionic acid
heteroaryl
Prior art date
Application number
UAA200709387A
Other languages
English (en)
Inventor
Збигнев Майка
Катажина Русин
Доминик Клудкевич
Даниэль Суликовски
Кшистоф Куровски
Катажина Матусевич
Томаш Ставински
Пьётр Ковальчик
Original Assignee
Адамед Сп. З О.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адамед Сп. З О.О. filed Critical Адамед Сп. З О.О.
Publication of UA89940C2 publication Critical patent/UA89940C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36One oxygen atom
    • C07D263/38One oxygen atom attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA200709387A 2005-01-19 2006-01-17 3-phenylpropionic acid derivatives UA89940C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL372332A PL372332A1 (pl) 2005-01-19 2005-01-19 Nowe związki, pochodne kwasu 3-fenylopropionowego

Publications (1)

Publication Number Publication Date
UA89940C2 true UA89940C2 (en) 2010-03-10

Family

ID=36046977

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200709387A UA89940C2 (en) 2005-01-19 2006-01-17 3-phenylpropionic acid derivatives

Country Status (25)

Country Link
US (2) US7309791B2 (ru)
EP (1) EP1874745B1 (ru)
JP (1) JP2008527021A (ru)
KR (1) KR100889447B1 (ru)
CN (1) CN101098862A (ru)
AT (1) ATE448214T1 (ru)
AU (1) AU2006207492B8 (ru)
BR (1) BRPI0606501A2 (ru)
CA (1) CA2590575C (ru)
CY (1) CY1109678T1 (ru)
DE (1) DE602006010353D1 (ru)
DK (1) DK1874745T3 (ru)
ES (1) ES2336358T3 (ru)
HR (1) HRP20090647T1 (ru)
IL (1) IL183564A0 (ru)
MX (1) MX2007008114A (ru)
NO (1) NO20074173L (ru)
PL (2) PL372332A1 (ru)
PT (1) PT1874745E (ru)
RS (1) RS51215B (ru)
RU (1) RU2369602C2 (ru)
SI (1) SI1874745T1 (ru)
UA (1) UA89940C2 (ru)
WO (1) WO2006077206A1 (ru)
ZA (1) ZA200705889B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
EP1951692B1 (en) * 2005-11-07 2010-08-18 Irm Llc Oxazole and thiazole ppar modulator
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
AU2009323367B2 (en) * 2008-12-01 2013-05-23 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
SI3511319T1 (sl) * 2014-07-03 2023-10-30 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
US10080757B2 (en) 2016-03-11 2018-09-25 Wisconsin Alumni Research Foundation Inhibitors of UDP-galactopyranose mutase

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552125A (en) 1975-06-07 1979-09-05 Lilly Industries Ltd 2-acylamino oxazoles
JPS58125039A (ja) 1982-01-21 1983-07-25 Konishiroku Photo Ind Co Ltd 写真用2当量イエロ−カプラ−
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および2型糖尿病の治療におけるそれらの使用
AU1961695A (en) 1994-03-12 1995-10-03 Yuhan Corporation Triazole compounds and processes for the preparation thereof
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
RU2176999C2 (ru) 1997-10-02 2001-12-20 Санкио Компани, Лимитед Производные амидокарбоновой кислоты, фармацевтическая композиция на их основе и способ снижения глюкозы в крови
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
US6506781B1 (en) 1999-09-08 2003-01-14 Smithkline Beecham Corporation Oxazole PPAR antagonist
FR2808798A1 (fr) 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
JP2004536152A (ja) 2001-07-30 2004-12-02 ノボ ノルディスク アクティーゼルスカブ 新規ビニルn−(2−ベンゾイルフェニル)−l−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
WO2003011834A1 (en) 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
PL371841A1 (pl) 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl) 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego

Also Published As

Publication number Publication date
KR20070097112A (ko) 2007-10-02
CN101098862A (zh) 2008-01-02
KR100889447B1 (ko) 2009-03-24
JP2008527021A (ja) 2008-07-24
IL183564A0 (en) 2007-09-20
US7309791B2 (en) 2007-12-18
AU2006207492B8 (en) 2009-03-26
DK1874745T3 (da) 2009-12-21
RU2369602C2 (ru) 2009-10-10
BRPI0606501A2 (pt) 2009-06-30
CY1109678T1 (el) 2014-08-13
RU2007131423A (ru) 2009-02-27
CA2590575C (en) 2010-09-21
PT1874745E (pt) 2010-01-13
US20060160868A1 (en) 2006-07-20
NO20074173L (no) 2007-08-14
WO2006077206A1 (en) 2006-07-27
ZA200705889B (en) 2009-03-25
ES2336358T3 (es) 2010-04-12
MX2007008114A (es) 2007-08-02
EP1874745A1 (en) 2008-01-09
DE602006010353D1 (de) 2009-12-24
US20070161799A1 (en) 2007-07-12
SI1874745T1 (sl) 2010-02-26
PL1874745T3 (pl) 2010-03-31
AU2006207492B2 (en) 2009-03-05
EP1874745B1 (en) 2009-11-11
HRP20090647T1 (hr) 2010-01-31
CA2590575A1 (en) 2006-07-27
US7629370B2 (en) 2009-12-08
ATE448214T1 (de) 2009-11-15
RS51215B (sr) 2010-12-31
PL372332A1 (pl) 2006-07-24
AU2006207492A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
MY142807A (en) Benzimidazole derivative and use thereof.
DE60022366D1 (de) Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
TW200616994A (en) Novel thiophene derivatives
TW200642683A (en) Heterocyclic compound
NZ514477A (en) Adamantane derivatives
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
SG160195A1 (en) N-phenyl-2-pyrimidine-amine derivatives
NO20054852L (no) GFAT inhibitorer
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
WO2003028728A8 (en) 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands
UA89940C2 (en) 3-phenylpropionic acid derivatives
NO20050087L (no) N-benzoylureido-kanelsyrederivater, fremgangsmate for fremstilling og anvendelse av disse
UA89807C2 (ru) Производные 3-фенилпропионовой кислоты для лечения диабета
WO2003028732A1 (fr) Antagoniste de recepteur
AU2003207808A1 (en) Peroxisome proliferator activated receptor modulators
NO20073330L (no) Sulfanylsubstituerte fenylmetanoner som glycintransportor 1 (glyt-1) inhibitorer for behandling av nevrologiske og nevropsykiatriske forstyrrelser
SG146627A1 (en) Imidazole derivatives
MEP12408A (en) Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors
WO2003027077A1 (fr) Derives de phenylpyridazine solubles dans l'eau et medicaments contenant ceux-ci
TW200509927A (en) Chronic obstructive pulmonary disease therapeutic agent and method of treating chronic obstructive pulmonary disease using the same